Pharmacy Trade Publications:
As Seen In...
Zestra® Feminine Arousal Fluid was recently advertised in Chain Drug Review
|
Latest News and Information
Zestra® -- First Clinically Proven Arousal Solution for Women -- To Exhibit at The American College of Obstetricians and
Gynecologists ''ACOG'' Annual Conference
|
|
CHARLESTON, S.C.--(BUSINESS WIRE)--May 9, 2005--QualiLife Pharmaceuticals, Inc., a science-driven company focused on developing and
commercializing meaningful consumer products for the sexual health marketplace, will exhibit Zestra® at the upcoming American
College
of Obstetricians and Gynecologists Conference ("ACOG"), in San Francisco May 7-11, 2005. Non-prescription Zestra® is the only
clinically proven topical product available for women who experience sexual difficulties.
View the entire release...
|
|
Dietary supplements for female sexual dysfunction
|
|
"A randomized, double-blind, placebo-controlled trial studied the effects of Zestra® in 20 women with and without FSAD.23 Applicants
were
evaluated with the FSFI and FSDS questionnaires. Women with FSAD had baseline scores of 4060 on the FSDS, and non-FSAD women had
baseline scores of <40 on the FSDS. (The FSDS ranges from 0 to 80, with lower scores generally indicating normal function.) All
participants were allowed to continue current medications, including antidepressants, nutritional supplements, and hormone replacement
therapy. Sexual pain or an FSDS score of >60 would exclude patients from participation. Each patient was given five vials of Zestra®
or
placebo and a diary (the Female Sexual Encounter Profile [FSEP]). After the patients used all five vials, they returned and completed
the FSFI, the FSDS, two global assessment questionnaires (GAQs), and the QualiLife Consumer Testing Survey (QCTS). Then they received
the crossover vials and a new diary and returned to complete the questionnaires again. Zestra® produced significant improvement in
FSEP,
FSFI, GAQ, and QCTS scores. The primary outcome measure, sexual arousal, showed a mean ± S.D. improvement (on a 01 scale) of 0.22 ±
0.28 (p = 0.03). There were no significant changes in FSDS scores. In addition, the researchers compared data between patients taking
and not taking SSRIs; there was no significant difference. It was concluded that Zestra® improved sexual function in all subjects,
regardless of FSAD diagnosis or SSRI use. Some patients reported that Zestra® caused mild burning or tingling that resolved within
30
minutes. No other adverse effects were reported."
View the American Journal of Health Full-Text Article.
 View the American Journal of Health PDF.
View the Pub
Med abstract. |
|
US Pharmacist - The Journal for Pharmacists' Education
|
|
QualiLife Pharmaceuticals has released Zestra® Feminine Arousal Fluid, an OTC containing natural, edible botanical ingredients. A
published clinical study shows that when applied to the
external female genitalia, the topical product enhances women's sexual arousal and pleasure during vaginal intercourse and manual stimulation. It can alleviate sexual difficulties due to
menopause or SSRI use. Each box contains nine single-use foil packets. The oil-based product can be used with polyurethane condoms.
View the entire Product News Excerpt
|
|
|
|
Drug Store News - The Business of Chain Pharmacy
Drug Store News has been the voice of the retail drug industry
for over seven decades. Forty thousand industry professionals
read this publication for its timely coverage of industry news,
merchandising trends and pharmacy developments. Its
authoritative articles and studies provide extensive coverage of
every major segment of chain drug retailing and combination
stores, keeping it number one in readership.
View Excerpts from the Reporter's Notebook
|
|
|
|
Pharmacy Times - Practical Information for Today's Pharmacist
Zestra® for Women is a botanical feminine massage oil formulated to enhance female sexual pleasure and arousal when applied to the
vulva. We conducted
this randomized, double-blinded, crossover study to evaluate the efficacy and safety of Zestra® for Women compared to placebo oil in
10 women with and
10 women without female sexual arousal disorder (FSAD) in conditions of home use in conjunction with sexual activities...
View the Hot OTC product description
|
|
Featured In:
  
* Click on one of the above logos to view it's article details.
|
|
